For FY2024, Roche Bobois SA will propose, at the next Annual General Meeting to be held on June 12, 2025, a dividend of 1.25 € per share, which corresponds to 80% of net income. For FY2025, Roche ...

Castles are made for infiltrating in Assassin's Creed Shadows. Trust me - you're going to be visiting a lot of them during your time in Japan! Whether you're looking for resources to smuggle, new ...

Swiss pharmaceutical company Roche announced Friday it will open an innovation center in the Harvard University Enterprise Research Campus in Allston that could employ hundreds. The Roche ...

However, nestled in the English countryside is a village so enchanting that it rivals the beauty of Switzerland - without the hefty price tag. Castle Combe, located in the Cotswolds, is often ...

Osaka Castle in Assassin's Creed Shadows is one of the areas you can visit in the early portion of the game, and though many enemies await inside, there's a chest full of legendary loot waiting to ...

Today, Roche is headquartered in Basel, Switzerland. The company now employs 80,000 people across a number of pharmaceutical and diagnostic sites across the world. The first of many successes ...

The Prehistoric Pile Dwellings Around the Alps in Switzerland was just named the most stunning UNESCO World Heritage Site ...

Roche Castle is one of the most impressive Anglo Norman castles in Ireland. Situated 7km north west from Dundalk, its hilltop location offers spectacular views of the surrounding countryside.

Texas just so happens to be home to a handful of castles capable of satisfying any fantasy lover. Heck, San Antonio Spurs rookie Stephon Castle should even grab himself a castle. While not for ...

Basel, March 7, 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today the launch of the Roche Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus in Allston which ...

For every charming chalet-filled village, there’s a contemporary city center full of Michelin-starred cuisine and luxury ...

Roche’s anti-TIGIT drug tiragolumab has failed a lung cancer study, denting enthusiasm for the programme just as there were signs that it was getting back on track after a series of ...